St. Francis’ X-Stop Gets FDA Green Light To Treat Lumbar Spinal Stenosis
This article was originally published in The Gray Sheet
Executive Summary
St. Francis Medical Technologies will begin marketing the X-Stop non-fusion device for lumbar spinal stenosis in January to experienced surgeons in order to build the product's reputation
You may also be interested in...
Ortho Panel Green Lights VertiFlex’s Superion Spine Spacer
A majority of FDA advisors say the device intended to treat lumbar spinal stenosis has a positive risk-benefit profile but should require an extended postmarket trial to evaluate its safety and efficacy over a longer time period.
Increased CDRH Post-Approval Vigilance Plays Out In Medtronic X-Stop Trials
Medtronic clinical executive Ruchir Sehra says CDRH's newfound rigor in the postmarket area is evident in its approach to the firm's post-approval study of the X-Stop spinal implant
Increased CDRH Post-Approval Vigilance Plays Out In Medtronic X-Stop Trials
Medtronic clinical executive Ruchir Sehra says CDRH's newfound rigor in the postmarket area is evident in its approach to the firm's post-approval study of the X-Stop spinal implant